NCT05379296 (HH) is a NA clinical trial of Diabetes Prevention Program Plus (DPP+) in Prediabetic State, sponsored by The University of Texas Medical Branch, Galveston.

Who is sponsoring NCT05379296?

NCT05379296 is sponsored by The University of Texas Medical Branch, Galveston.

What drugs are being tested in NCT05379296?

Interventions in NCT05379296: Diabetes Prevention Program Plus (DPP+), Diabetes Prevention Program (DPP).

What condition does NCT05379296 study?

NCT05379296 studies Prediabetic State, Gestational Weight Gain, Hypertension, Overweight or Obesity.

Is NCT05379296 still recruiting?

NCT05379296 is currently withdrawn. Last updated 27 January 2023.

Last reviewed 2023-01-27 · How we verify

NCT05379296: HH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Healthy Hearts: Leveraging the Diabetes Prevention Program to Decrease Health Disparities in Women of Reproductive Age

Withdrawn NA Last updated 27 January 2023

What this trial tests

NA trial testing Diabetes Prevention Program Plus (DPP+) in Prediabetic State. Withdrawn.

Timeline

1 January 2022

Primary endpoint
20 January 2023

20 January 2023

Quick facts

Lead sponsor	The University of Texas Medical Branch, Galveston
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Start date	1 January 2022
Primary completion	20 January 2023
Estimated completion	20 January 2023

Drugs / interventions tested

Diabetes Prevention Program Plus (DPP+)
Diabetes Prevention Program (DPP)

Conditions studied

Prediabetic State — all drugs for Prediabetic State →
Gestational Weight Gain — all drugs for Gestational Weight Gain →
Hypertension — all drugs for Hypertension →
Overweight or Obesity — all drugs for Overweight or Obesity →

Sponsor

The University of Texas Medical Branch, Galveston

Who can join

Adults 18 to 45, female only, with Prediabetic State or Gestational Weight Gain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nearly half of women have obesity and/or hypertension (HTN). Specific to women, pregnancy creates a vulnerable window for excess gestational weight gain (GWG), exacerbating intergenerational risks for obesity, HTN, type 2 diabetes (T2D), and cardiovascular disease (CVD) across the lifespan. Healthy lifestyles are the first-line recommendations for prevention and treatment of overweight/obesity, HTN, T2D, and CVD. The Diabetes Prevention Program (DPP) is a well-established, Centers for Disease Control and Prevention (CDC)-led public health program focusing on healthy lifestyle changes and is effective at reducing 5-7% of body weight, lowering risks for T2D. Interestingly, research investigating the DPP as a lifestyle intervention for other chronic conditions (i.e., overweight/obesity and HTN) is lacking, demonstrating a missed opportunity. The aim of this study is to determine the initial effects of the first 6-months and after receiving the full 12-months of the virtual DPP compared to the DPP expanded with a CDC-approved HTN prevention component (DPP+) on physical activity, diet, weight, and CVD risk factors in 30 prediabetic women (18-45 years old) with a history of excess GWG, overweight/obesity, and HTN. Participants will be recruited through University of Texas Medical Branch (UTMB) community-based clinics using Epic. The Participants will be randomized into 2 groups (DPP and DPP+) and guided through the 12-month virtual DPP or DPP+ program using UTMB DPP personnel.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Prediabetic State

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT06897982 — Feasibility of a Nutrition Intervention for Patients With Prediabetes at a Federally Qualified Health Center · NA · recruiting
NCT06118931 — Time-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic Control · NA · recruiting
NCT06471569 — Role of Aging and Individual Variation in Exercise Training Responsiveness · NA · recruiting
NCT06723886 — Antidiabetic Effect of Olive Pomace Oil · NA · recruiting

Other The University of Texas Medical Branch, Galveston trials

Trials by the same sponsor.

NCT04095260 — Identification of Neuromusculoskeletal Variables Associated With Injury Risk and Performance in High School Athletes. · not yet recruiting
NCT06800092 — Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment · Phase 2, PHASE3 · not yet recruiting
NCT07337915 — Improving Sleep In Midlife Women · NA · recruiting
NCT07203287 — Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease · Phase 4 · recruiting
NCT07087743 — Virtual Reality-Integrated Propulsion Feedback for Stroke Rehab · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05379296 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Medical Branch, Galveston
Last refreshed: 27 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05379296.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing